SA519410672B1 - تركيبات إنسولين سريعة المفعول - Google Patents

تركيبات إنسولين سريعة المفعول

Info

Publication number
SA519410672B1
SA519410672B1 SA519410672A SA519410672A SA519410672B1 SA 519410672 B1 SA519410672 B1 SA 519410672B1 SA 519410672 A SA519410672 A SA 519410672A SA 519410672 A SA519410672 A SA 519410672A SA 519410672 B1 SA519410672 B1 SA 519410672B1
Authority
SA
Saudi Arabia
Prior art keywords
rapid
acting insulin
insulin compositions
insulin
compositions
Prior art date
Application number
SA519410672A
Other languages
English (en)
Inventor
زهانج جون
دونالد بافولا شاد
Original Assignee
ايلاي ليلى اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلاي ليلى اند كومباني filed Critical ايلاي ليلى اند كومباني
Publication of SA519410672B1 publication Critical patent/SA519410672B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

يتعلق الاختراع الحالي بتركيبة إنسولين insulin composition أو نظير إنسولين insulin analog تتسم بمفعول حركي دوائي pharmacokinetic action أسرع من الصيغ التجارية لمنتجات نظير الإنسولين سريعة بدء المفعول rapid-onset insulin analog products.
SA519410672A 2017-06-01 2019-11-28 تركيبات إنسولين سريعة المفعول SA519410672B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513645P 2017-06-01 2017-06-01
PCT/US2018/035261 WO2018222787A1 (en) 2017-06-01 2018-05-31 Rapid-acting insulin compositions

Publications (1)

Publication Number Publication Date
SA519410672B1 true SA519410672B1 (ar) 2022-06-16

Family

ID=62779004

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519410672A SA519410672B1 (ar) 2017-06-01 2019-11-28 تركيبات إنسولين سريعة المفعول

Country Status (25)

Country Link
US (1) US11207384B2 (ar)
EP (1) EP3630166B1 (ar)
JP (1) JP6920471B2 (ar)
KR (2) KR102342865B1 (ar)
CN (1) CN110662551B (ar)
AU (1) AU2018275545B2 (ar)
BR (1) BR112019022212A2 (ar)
CA (1) CA3065308C (ar)
CL (1) CL2019003336A1 (ar)
CO (1) CO2019013251A2 (ar)
CR (1) CR20190522A (ar)
DO (1) DOP2019000300A (ar)
EA (1) EA201992351A1 (ar)
EC (1) ECSP19085451A (ar)
ES (1) ES2912162T3 (ar)
IL (1) IL270975B2 (ar)
JO (1) JOP20190277B1 (ar)
MA (1) MA50496A (ar)
MX (1) MX2019014195A (ar)
NZ (1) NZ758298A (ar)
PE (1) PE20200017A1 (ar)
PH (1) PH12019502677A1 (ar)
SA (1) SA519410672B1 (ar)
UA (1) UA126450C2 (ar)
WO (1) WO2018222787A1 (ar)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018609B1 (de) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
AU612141B2 (en) 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5547942A (en) 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
ATE220917T1 (de) 1999-01-26 2002-08-15 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
RU2300367C2 (ru) 1999-11-15 2007-06-10 Ханамарадди Т. ГАНГАЛ Жидкий лечебный состав для внутривенного введения, содержащий декстрозу и инсулин
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE10351594A1 (de) * 2003-11-05 2005-06-16 Tecpharma Licensing Ag Vorrichtung für die Verabreichung eines injizierbaren Produkts
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
PT2319500E (pt) 2004-03-12 2013-01-23 Biodel Inc Composições de distribuição de fármacos de actuação rápida
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
AU2008259768B2 (en) 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
CA2805031A1 (en) 2010-07-07 2012-01-12 Biodel, Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
AU2012271361B2 (en) 2011-06-17 2017-03-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
MX361727B (es) 2011-12-30 2018-12-14 Halozyme Inc Variantes de polipeptido ph20, formulaciones y usos de las mismas.
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
EA034393B1 (ru) 2012-11-13 2020-02-03 Адосиа Состав инсулина быстрого действия, содержащий замещенное анионное соединение
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
KR102351111B1 (ko) 2014-01-13 2022-01-14 써멀린 다이어비티즈, 엘엘씨 초속효성 인슐린 제형 및 약제학적 전달 시스템
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
JO3624B1 (ar) 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US9795678B2 (en) * 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
US20180221385A1 (en) 2015-07-28 2018-08-09 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
US11247996B2 (en) 2016-07-29 2022-02-15 University Of Massachusetts Small molecule inhibitors for transcription factors
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations

Also Published As

Publication number Publication date
JOP20190277B1 (ar) 2023-09-17
CO2019013251A2 (es) 2020-01-17
AU2018275545B2 (en) 2021-02-04
US20200078446A1 (en) 2020-03-12
PH12019502677A1 (en) 2020-06-08
DOP2019000300A (es) 2019-01-15
CA3065308A1 (en) 2018-12-06
JOP20190277A1 (ar) 2019-11-28
US11207384B2 (en) 2021-12-28
AU2018275545A1 (en) 2019-10-31
ES2912162T3 (es) 2022-05-24
BR112019022212A2 (pt) 2020-05-12
MA50496A (fr) 2020-09-09
CA3065308C (en) 2022-05-17
CL2019003336A1 (es) 2020-05-15
CN110662551B (zh) 2023-07-18
IL270975B1 (en) 2023-10-01
MX2019014195A (es) 2020-01-27
IL270975B2 (en) 2024-02-01
EP3630166A1 (en) 2020-04-08
JP6920471B2 (ja) 2021-08-18
ECSP19085451A (es) 2019-12-27
KR102342865B1 (ko) 2021-12-24
JP2020522470A (ja) 2020-07-30
NZ758298A (en) 2022-11-25
UA126450C2 (uk) 2022-10-05
KR20210106029A (ko) 2021-08-27
KR20190140048A (ko) 2019-12-18
CN110662551A (zh) 2020-01-07
WO2018222787A1 (en) 2018-12-06
IL270975A (en) 2020-01-30
PE20200017A1 (es) 2020-01-06
CR20190522A (es) 2020-01-15
EP3630166B1 (en) 2022-04-06
EA201992351A1 (ru) 2020-03-26

Similar Documents

Publication Publication Date Title
PH12016502195A1 (en) Rapid- acting insulin compositions
PH12018500422B1 (en) Rapid-acting insulin compositions
AU2015317711B2 (en) Compositions comprising recombinant Bacillus cells and another biological control agent
WO2019020602A3 (en) LUMINOPHORE AND COMPOSITION
WO2016050890A3 (en) Methods and materials for biosynthesis of mogroside compounds
MX2019015018A (es) Composiciones que comprenden curones y usos de los mismos.
AU2015317715A8 (en) Compositions comprising recombinant Bacillus cells and a fungicide
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2020001885A (es) Formulaciones de daptomicina.
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MY190102A (en) Tolerogenic dna vaccine
MX2021004115A (es) Derivados de alcoxibenzaldehido y precursores de los mismos.
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
SA519410672B1 (ar) تركيبات إنسولين سريعة المفعول
EP3676612A4 (en) COMPOSITION FOR THE STABILIZATION OF ANTIBODY FORMULATIONS CONTAINING PERCP
MX2017001760A (es) Composiciones mejoradas de la goma de mascar y metodos de fabricacion de esta.
EP3687539A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS OF DALFAMPRIDINE
MX2015015850A (es) Composiciones de sabor y fragancia que contienen tiopiran-carbaldehido.
PL409786A1 (pl) Zastosowanie 3-metylo-1-n-propoksybutanu do wytwarzania kompozycji zapachowych